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Summary
Objective: Epilepsy is one of the most common neurological conditions
affecting about 1% of adults. Up to 40% of people with epilepsy (PWE) report
recurring seizures while on medication. And optimal functioning requires good
self-management. Our objective was to evaluate a group self-management
education courses for people with epilepsy and drug-resistant seizures
by means of a multicenter, pragmatic, parallel group, randomized controlled
trial.
Methods: We recruited adults with epilepsy, having ≥2 seizures in the prior
12 months, from specialist clinics. Consenting participants were randomized 1:1 to
a group course or treatment as usual. The primary outcome measure was quality of
life 12 months after randomization using Quality of Life 31-P (QOLIE-31-P). Sec-
ondary outcome measures were seizure frequency and recency, psychological dis-
tress, impact and stigma of epilepsy, self-mastery, medication adherence, and
adverse effects. Analysis of outcomes followed the intention-to-treat principle
using mixed-effects regression models.
Results: We enrolled 404 participants (intervention: n = 205, control: n = 199)
with 331 (82%) completing 12-month follow-up (intervention: n = 163, control:
n = 168). Mean age was 41.7 years, ranging from 16 to 85, 54% were female
and 75% were white. From the intervention arm, 73.7% attended all or some of
the course. At 12-month follow-up, there were no statistically significant differ-
ences between trial arms in QOLIE-31-P (intervention mean: 67.4, standard devi-
ation [SD]: 13.5; control mean: 69.5, SD 14.8) or in secondary outcome
measures.
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Significance: This is the first pragmatic trial of group education for people with
poorly controlled epilepsy. Recruitment, course attendance, and follow-up rates
were higher than expected. The results show that the primary outcome and quality
of life did not differ between the trial arms after 12 months. We found a high
prevalence of felt-stigma and psychological distress in this group of people with
drug-resistant seizures. To address this, social and psychological interventions
require evaluation, and may be necessary before or alongside self-management-
education courses.
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1 | INTRODUCTION
Epilepsy is one of the most common neurological conditions
affecting about 1% of adults.1 Despite the use of drugs, about
40% of people with epilepsy (PWE) report recurring sei-
zures.2 Recurring seizures increase the risk of injury, hospital
admission, depression, and death.3–5 Seizure control depends
on appropriate medication and, as in other long-term condi-
tions, on self-management.6 PWE express the need for more
information about their condition in order to achieve this.6–8
A 2-day self-management education course, “Modular
Service Package Epilepsy” (MOSES), was evaluated for
adults with epilepsy in German-speaking countries, and a
randomized-controlled trial (RCT) demonstrated improved
knowledge, coping, and seizure frequency after 6 months.9 It
was subsequently offered to PWE in Germany, with health
insurers reimbursing the cost. We know of no other epilepsy
self-management course with such widespread uptake. In the
United Kingdom (UK), courses for people with other condi-
tions such as diabetes have been tested, and are now freely
accessible.10,11
In this context, our research group responded to a commis-
sioned call to test an English-language version of MOSES,
which we adapted for use in the UK and called it: Self-man-
agement education for people with poorly controlled epilepsy
(SMILE [UK]). German MOSES leaders trained UK Epi-
lepsy Nurse Specialists and electroencephalography (EEG)
technicians to deliver the course. We also undertook an exter-
nal pilot with volunteers to test the feasibility and acceptabil-
ity of delivering SMILE (UK) in the context of the National
Health Service (NHS).12 This paper addresses the question:
for people with poorly controlled epilepsy, does the SMILE
(UK) self-management course improve quality of life?
2 | METHODS
The trial was conducted and reported in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines. A detailed description of the trial design, inter-
ventions, and outcome measures can be found in the pub-
lished trial protocol.13 Here we provide a brief overview.
2.1 | Trial design
This was a parallel arm, multicenter, randomized con-
trolled trial (or RCT). Participants were randomly allocated
to 1 of 2 trial arms: the SMILE (UK) training program
plus treatment-as-usual (TAU) or TAU only. Assessments
were performed at baseline prior to randomization, and
6- and 12-months after randomization. The intervention
was offered to the control group after their 12-month
assessment.
2.2 | Trial setting
PWE were recruited from specialist epilepsy clinics at 8
hospitals in London and South East England between
December 2013 and August 2016.
Key Points
• Largest randomized controlled trial (RCT) of a
group course for people with chronic, drug-resis-
tant epilepsy achieved good participation and fol-
low-up
• Mean quality of life (QoL) was comparatively
high at baseline, 54% had anxiety and 28%
depression symptoms, and 63% felt stigmatized
• At 12-month follow-up, QoL and other outcomes
were not different between the intervention and
treatment-as-usual groups
• A group course was well-received by people
with chronic, drug-resistant epilepsy but was not
sufficient to change quality of life after
12 months
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2.3 | Standard protocol approvals,
registrations, and patient consents
The study was approved by the National Research Ethics
Service Committee London—Fulham (REC reference 12/
LO/1962) and monitored by independent Data Monitoring
(DMC) and Trial Steering Committees (TSC). Patients gave
written informed consent to participate in the study. Trial
registration: Current Controlled Trials ISRCTN57937389.
2.4 | Patient recruitment
Stage 1: Neurologists sent letters to potentially eligible
patients under their care informing them of the trial. Patients
had 3 weeks to return an opt-out response if they did not
wish to proceed to the next stage. Stage 2: If an opt-out slip
was not received, their medical notes were reviewed by the
research team to confirm eligibility. Those eligible were sent
a letter from the research team inviting them to participate in
the trial. Again, potential participants had 3 weeks to opt out
of the next stage. Stage 3: Those who did not opt out were
telephoned to discuss the trial and confirm eligibility if inter-
ested. Participants then gave written informed consent during
a face-to-face interview with a researcher.
2.5 | Eligibility criteria
Eligibility criteria were the following: aged ≥16 years, hav-
ing a diagnosis of epilepsy made by a specialist for
≥1 year, prescribed antiepileptic drugs (AEDs), reporting at
least 2 seizures (of any type) in the previous year, able to
give informed consent, answer questionnaires in English,
and attend a 2-day course.
Patients were excluded if they only experienced psy-
chogenic nonepileptic seizures or due to acute illness or
substance misuse, serious psychiatric illness or a terminal
condition, or if they were currently participating in other
epilepsy-related research.
2.6 | Randomization and blinding
Randomization was provided by an online system managed
by the King’s Clinical Trials Unit, maintaining full alloca-
tion concealment.13,14 Randomization occurred in blocks of
2 (1:1 intervention: control) and was stratified by treatment
center. Research staff who completed follow-up assess-
ments and the patients’ healthcare providers were blinded
to treatment allocation. Due to the nature of the interven-
tion, participants were not blinded, although they were
asked not to reveal their allocation to the researchers who
completed their follow-up assessments. Staff who were
organizing the SMILE (UK) courses were not involved in
data collection and were not blinded to allocation. The trial
statistician remained blind until the end of the analysis,
when the final parts that cannot be performed blind were
completed, such as training group effects and treatment
compliance.
2.7 | Intervention
The intervention was a 2-day group education course on
self-management, based on MOSES, for people with poorly
controlled epilepsy, with carers also invited.9 We aimed for
groups to include 8-12 participants. The course was
16 hours over 2 consecutive days delivered by an epilepsy
nurse specialist and an electroencephalography (EEG) tech-
nician. The premise of the course was to communicate
information and to encourage participants to share their
own experiences with others. Participants were given a
workbook containing course content to use during the ses-
sions and to take home. The course’s content is presented
briefly in Table 1, with further information available else-
where.15 A fidelity implementation found that trainers
within the trial delivered the intervention according to pro-
tocol, with good adherence and high competence.15
2.8 | Measures
Clinical and psychosocial data were collected face-to-face
at baseline prior to randomization. At baseline and at
12 months after randomization, primary and all secondary
outcome measures were assessed. A postal 6-month fol-
low-up assessment included a subset of the outcome mea-
sures. Full details of all the measures taken can be found
in the published protocol13 and Table S1. The time points
were selected to assess long-term effectiveness of the
course, in terms of scientific findings, and to assess the
relative benefit in the context of commissioning health-
care.
2.8.1 | Primary outcome
The primary outcome was epilepsy-specific quality of life
(QoL) 12 months after randomization. Because the MOSES
trial had no effect on a generic QoL measure,9 a health-spe-
cific scale was chosen, QOLIE-31-P (Quality of Life in Epi-
lepsy-3116 with added Patient-specific weightings).17 This
scale had the benefit of introducing patient’s scoring of how
aspects of QoL distressed them, thus adding more weight to
the elements impacting their perception of QoL. In addition,
the mean unadjusted total score was calculated by removing
the patient weights (total QOLIE-31), which permitted com-
parison with prior studies. The total score is out of a maxi-
mum of 100, where high scores mean good QoL.
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2.8.2 | Secondary outcomes
These comprised seizure frequency scales,3,18 seizure
recency (number of days since last seizure), Hospital Anxi-
ety and Depression Scale (HADS)19 for psychological dis-
tress (anxiety and depression), Impact of Epilepsy,20,21
Stigma of Epilepsy,22 Medication Adherence,23 medication
adverse effects extracted from the QOLIE-31-P,17 and Self-
Mastery and Control.24 Only, the QOLIE-31-P, seizure fre-
quency and recency, and Impact of Epilepsy were com-
pleted at the 6-month follow-up.
2.9 | Sample size
The sample size calculation is explained in full in the pub-
lished protocol and analysis plan.13,14 The original calcula-
tion required a total of N = 428 participants to be
randomized, providing 91.3% power to detect an effect size
of d = 0.4 on the QOLIE-31-P scale at 12 months, assum-
ing an attrition rate of 25%.
2.10 | Statistical analyses
A detailed statistical analysis plan (SAP) was written, dis-
cussed by the DMC and signed off by the TSC prior to
database lock.14
All outcomes were analyzed using the intention-to-treat
(ITT) approach. Multiple imputation by chained equations
(MICE) was used to impute missing outcome variables at
all time points to produce inferences valid under the
detected missing-at-random data generating process. This
was necessary because treatment compliance within the
intervention arm, defined as attending the beginning and
end of each day of the course, was found to be predictive of
missing primary outcome data according to a chi-square test
(P < .001). Univariable logistic regression was used to
TABLE 1 SMILE (UK) course content and self-management components
Module Content Self-management component
Living with
epilepsy
Sharing personal experience and emotions felt when living
with epilepsy. How to cope with these emotions
Addressing psychological comorbidity by discussing anger
and anxiety.
Increasing resilience by identifying coping strategies
People with
epilepsy
Discussion of how common epilepsy is and about
famous people who have epilepsy
Reducing stigma by discussing how common epilepsy is and
the achievements of PWE
Basic
knowledge
Causes of seizures and different seizure types Increasing knowledge that leads to participants becoming
“experts” in their epilepsy increases self-confidence
Diagnosis Investigations used to diagnose epilepsy. How to observe
and document seizures to help diagnosis
Improving seizure control.
Addressing psychological comorbidity by reducing anxiety
about medical procedures
Treatment Overview of antiepileptic drugs, other treatments.
How to take an active role in one’s treatment
Improving seizure control.
Preventing/reducing risk of injury.
Improving medication adherence.
Addressing psychological comorbidity by understanding
medication adverse effects and increasing self-confidence
in future discussions with healthcare professionals
Self-control Identifying auras and triggers. How to avoid triggers.
Methods to reduce seizures
Improving seizure control.
Preventing/reducing risk of injury.
Addressing psychological comorbidity by improving
seizure control
Prognosis Chances of achieving seizure freedom and stopping
medication. Other options if seizure freedom is not achieved
Reducing stigma by discussing what can still be achieved
if not seizure-free
Personal and
social life
Sharing how epilepsy affects personal and professional
relationships. How to improve self-esteem and develop
contacts. Explaining epilepsy to others. Recommendations
for hobbies, sports, independent living. Regulations about
driving and employment
Preventing/reducing risk of injury.
Addressing psychological comorbidity by improving
self-esteem and identifying own qualities and weaknesses,
how to seek psychological support, problem solving to pursue
active lifestyle and live independently.
Reducing stigma by reducing unnecessary restrictions on
activities, creating and maintaining social contacts, reducing
isolation, legislation and entitlements for disabilities
Epilepsy
network
Information about available resources, user groups,
charities, and psychological support
Reducing stigma by identifying support groups
and organizations
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detect whether any baseline variables predicted missing-
ness. Being male, education to degree level (vs no formal
qualifications) and having no other significant medical
conditions (vs having a psychiatric condition) were associ-
ated with completion of primary outcome data at
12 months. Treatment compliance (in the intervention arm)
and baseline predictors of missingness were therefore
included in the imputation step of the MICE procedure as
fixed effects, as well as: measures of the outcome at all
time points; training group in the SMILE (UK) arm; and
all the variables forming the analysis model. This ensured
that the imputation model was more general than the anal-
ysis model.
The analysis model for the primary outcome was a lin-
ear mixed model. It consisted of the dependent variable
QOLIE-31-P at 12 months, with fixed explanatory vari-
ables: trial arm (SMILE [UK] vs TAU), using TAU as
the reference category; randomization stratifier (dummy
variable for treatment center); and baseline QOLIE-31-P.
Random effects were included for the training group in
the SMILE (UK) arm to account for shared group experi-
ences. We generated 100 imputed datasets and combined
analysis results according to Rubin’s rules.25 Standardized
treatment effect estimates, which are more appropriate for
comparisons, were also calculated by dividing the esti-
mated difference by the standard deviation of baseline
QOLIE-31-P.
Secondary outcomes were analyzed following a similar
approach, again using multiple imputation to allow for the
detected missing-at-random process. For QOLIE-31-P at
6 months and other continuous secondary outcome vari-
ables, linear mixed-effects models were used and standard-
ized effects were calculated.
At each time point (baseline, 6 and 12 months), seizure
recency was measured in terms of the number of days
since last recalled seizure. This was converted into a pro-
portion of time by dividing the number of seizure-free days
over the maximum number of seizure-free days possible
for that time point (1, 1.5, and 2 years), plus a recall bias
period of 6 months: 548 days; 730 days; and 913 days,
respectively. This proportion was then transformed into a
continuous variable using the logit transformation and ana-
lyzed in the same way as the other continuous variables.
The 2 seizure frequency variables, Baker18 (<1 vs ≥1
seizure per month) and Thapar3 (0-3 seizures, 4-6 sei-
zures, 7-9 seizures, or 10+ seizures in a year), were ana-
lyzed as binary and ordinal outcomes, respectively, using
a logistic mixed-effects model and an ordinal logistic
mixed-effects model. To aid interpretation, the estimated
treatment effects were exponentiated to produce odd-
ratios. Although both seizure frequency variables were
measured at 6 months and included in the imputation step
for the 12-month outcomes, they were not analyzed sepa-
rately as secondary outcomes because there was not a cor-
responding baseline measure for number of seizures in
the last 6 months.
A complier average causal effect (CACE) analysis
was carried out for the primary outcome to assess the
efficacy of SMILE (UK) in the presence of noncompli-
ance. For this, compliance with SMILE (UK) was again
defined as full receipt (attending all 4 sessions) vs non-
full receipt, irrespective of treatment allocation.
Statistical analyses were performed using Stata version
14.0.
3 | RESULTS
3.1 | Description of trial participants
Figure 1 provides a CONSORT diagram for this trial.
From those eligible in the final stage (n = 1088), 37.4%
consented into the study with 37.1% being randomized.
Once actual follow-up rates were established, the sample
size requirement was updated to N = 400 using an attrition
rate of 20%. Twelve-month follow-ups proved to be more
successful than anticipated. At 12-month, 81.9% of partici-
pants remained in the study (Intervention: 79.5%; TAU:
84.4%). Baseline data have been reported in full26 and are
presented in Table 2. Compared to the UK population,
more participants lived in deprived areas, but the charac-
teristics of the 2 trial arms, including gender, were well
balanced (Table 2). Baseline mean QOLIE-31-P score was
66.0, with a wide range of 24.8-98.5. The mean unad-
justed QOLIE-31 score was 62.0, ranging from 24.5 to
97.6.
3.2 | Intervention delivery and receipt, and
retention of participants
Eighteen 2-day courses were delivered and the mean group
size was 8 (range 5-14). The course was divided into 4
half-day sessions, with 61.5% of participants attending all
sessions, 12.3% attending 1-3, and 26% attending none
(Table S2). Reasons for not attending are detailed in
Table S3. Eighty-two percent of participants completed the
12-month follow-up assessment. Reasons for withdrawal
are listed in Table 3. Three participants from the TAU
group inadvertently attended the course prior to their
12-month follow-up due to administrative errors.
3.3 | Adverse events
There were no adverse events related to the intervention
(Table S4).
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3.4 | Study outcomes
3.4.1 | Primary outcome: quality of life
The ITT analysis did not detect an effect of the interven-
tion on total QOLIE-31-P scores (Cohen’s d = 0.05;
P = .564) at 12 months (Table 4). Thus, the intervention
could not be shown to be effective. The CACE analysis,
which defined 126 participants from the SMILE (UK) arm
and 3 participants from the TAU arm as “full treatment
compliers,” estimated an effect in the same direction and
which also was not statistically significant (P = .528).
Thus, there was also no evidence to suggest that the inter-
vention was efficacious when fully adhered to.
FIGURE 1 CONSORT diagram of participant recruitment and retention in the trial. Recruitment occurred through 3 stages, the first 2
requiring patients to opt out in order to not progress through the pathway. The third stage involved researchers contacting patients who did not opt
out at stages 1 and 2. Three participants who consented were not randomized, in error. At the 6-month follow-up, missing outcome data occurred
due to participants either not wanting to continue and formally withdrawing (n = 23 intervention; n = 15 TAU) or being presumed lost to follow-
up, that is, not returning postal questionnaires and being unreachable. Some of these participants who were presumed lost to follow-up remained in
the study and later participated in the 12-month follow-up. All participants not completing outcome data at the 12-month follow-up were
considered withdrawals (n = 19 intervention; n = 16 TAU), that is, this included participants not wanting to continue and those lost-to-follow-up
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TABLE 2 Baseline characteristics and outcome measures
Variable Level
Intervention
n = 205
TAU
n = 199
Total
n = 404
Age, mean (SD)
[range]
Years 42.5 (14.3) [16, 85] 40.8 (14.0) [17, 82] 41.7 (14.1) [16, 85]
Sex, n (%) Female 115 (56.1) 104 (52.3) 219 (54.2)
Male 90 (43.9) 95 (47.7) 185 (45.8)
Ethnicity, n (%) White 160 (78.0) 144 (72.4) 304 (75.2)
Mixed 19 (9.3) 21 (10.6) 40 (9.9)
Black 16 (7.8) 17 (8.5) 33 (8.2)
Asian 7 (3.4) 11 (5.5) 18 (4.5)
Other 3 (1.5) 6 (3.0) 9 (2.2)
IMD quintiles, n (%) 1 (least deprived) 20 (9.8) 19 (9.5) 39 (9.7)
2 27 (13.2) 29 (14.6) 56 (13.9)
3 33 (16.1) 31 (15.6) 64 (15.8)
4 70 (34.1) 66 (33.2) 136 (33.7)
5 (most deprived) 55 (26.8) 54 (27.1) 109 (27.0)
Highest level of
education, n (%)
No formal qualifications 31 (15.1) 30 (15.1) 61 (15.1)
Secondary level 69 (33.7) 62 (31.2) 131 (32.4)
Postsecondary education 44 (21.5) 41 (20.6) 85 (21.0)
Bachelor’s degree and higher 61 (29.8) 66 (33.2) 127 (31.4)
Living
arrangements, n (%)
Living with others 159 (77.6) 146 (73.4) 305 (75.5)
Living alone 43 (21.0) 52 (26.1) 95 (23.5)
Other arrangements 3 (1.5) 1 (0.5) 4 (1.0)
Marital status, n (%) Single 81 (39.7) 95 (48.0) 176 (43.8)
With partner, not cohabiting 23 (11.3) 21 (10.6) 44 (10.9)
Married/living with partner 83 (40.7) 70 (35.4) 153 (38.1)
Divorced/widowed 17 (8.3) 12 (6.1) 29 (7.2)
Employment, n (%) Employed full-time 42 (20.5) 46 (23.1) 88 (21.8)
Employed part-time 22 (10.7) 31 (15.6) 53 (13.1)
Self-employed 15 (7.3) 13 (6.5) 28 (6.9)
Other 32 (15.6) 26 (13.1) 58 (14.3)
Unemployed 94 (45.9) 83 (41.7) 177 (43.8)
Clinical details
Diagnosis of epilepsy,
median (IQR) [range]
Number of years 20 (8, 32) [1, 66] 18 (8, 32) [1, 64] 18 (8, 32) [1, 66]
Comorbidity, n (%) None 101 (49.3) 118 (59.3) 219 (54.2)
Another medical condition 71 (34.6) 61 (30.7) 132 (32.7)
Psychiatric condition 10 (4.9) 10 (5.0) 20 (5.0)
Both medical and psychiatric 23 (11.2) 10 (5.0) 33 (8.2)
Outcome measures
QOLIE-31-P, mean (SD)
[range] (higher score
reflects greater QoL)
Total score 65.2 (14.1)
[30.0, 91.6]
66.9 (14.2)
[24.8, 98.5]
66.0 (14.2)
[24.8, 98.5]
QOLIE-31, mean (SD)
[range] (higher score
reflects greater QoL)
Total score 60.9 (15.6)
[24.5, 93.7]
63.1 (15.7)
[24.7, 97.6]
62.0 (15.6)
[24.5, 97.6]
(Continues)
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TABLE 2 (Continued)
Variable Level
Intervention
n = 205
TAU
n = 199
Total
n = 404
Seizure frequency in last
12 months, (Thapar) n
(%)
0-3 times 19 (9.3) 30 (15.1) 49 (12.1)
4-6 times 29 (14.1) 22 (11.1) 51 (12.6)
7-9 times 15 (7.3) 9 (4.5) 24 (5.9)
10+ times 142 (69.3) 138 (69.3) 280 (69.3)
Seizure frequency in last
12 months, (Baker) n (%)
<1 per month 52 (26.1) 58 (29.6) 110 (27.8)
≥1 per month 147 (73.9) 138 (70.4) 285 (72.2)
Seizure recency in last
12 months, median (IQR)
[range]
Days since last
recalled seizure
33 (19, 64) [1, 351] 34 (17, 63) [3, 457] 34 (18, 63) [1, 457]
Impact of epilepsy, mean
(SD) [range] (higher score
reflects less impact)
Total score 24.4 (8.0) [10, 40] 24.4 (8.1) [10, 40] 24.4 (8.0) [10, 40]
Medication adherence,
median (IQR) [range]
(higher score reflects
greater adherence)
Total score 46.7 (43.3, 48.9)
[16.7, 50.0]
46.7 (43.3, 48.9)
[26.7, 50.0]
46.7 (43.3, 48.9) [16.7, 50.0]
Medication adverse effects,
median (IQR) [range]
(higher score reflects less
adverse effects)
Total score 7 (5, 10) [2, 10] 7 (4, 10) [2, 10] 7 (5, 10) [2, 10]
Anxiety (HADS-A), mean
(SD) [range] (higher score
reflects more anxiety
symptoms)
Total score 9.0 (5.0) [0, 21] 7.8 (4.8) [0, 21] 8.4 (4.9) [0, 21]
Anxiety categories (HADS-
A) n (%)
Normal: 0-7 83 (40.7) 104 (52.3) 187 (46.4)
Borderline: 8-10 44 (21.6) 35 (17.6) 79 (19.6)
Case: 11-21 77 (37.7) 60 (30.2) 137 (34.0)
Depression (HADS-D),
mean (SD) [range] (higher
score reflects more
depression symptoms)
Total score 5.5 (3.9) [0, 18] 5.0 (3.9) [0, 16] 5.3 (3.9) [0, 18]
Depression categories
(HADS-D), n (%)
Normal: 0-7 144 (70.6) 146 (73.4) 290 (72.0)
Borderline: 8-10 37 (18.1) 34 (17.1) 71 (17.6)
Case: 11-21 23 (11.3) 19 (9.5) 42 (10.4)
Stigma, median (IQR)
[range] (higher score
reflects greater stigma)
Total score 1 (0, 4) [0, 9] 2 (0, 4) [0, 9] 1 (0, 4) [0, 9]
Stigma categories, n (%) Not stigmatized: 0 76 (37.4) 72 (36.4) 148 (36.9)
Mild-moderate: 1-6 100 (49.3) 103 (52.0) 203 (50.6)
Highly stigmatized: 7-9 27 (13.3) 23 (11.6) 50 (12.5)
Self-mastery, mean (SD)
[range] (higher score
reflects more control)
Total score 13.9 (3.4) [6, 23] 14.3 (3.3) [6, 24] 14.1 (3.3) [6, 24]
IMD, Index of Multiple Deprivation indicates the level of deprivation according to the participant’s postcode. National data are tabulated by the Office of National
Statistics in the UK and distributed into quintiles, from lowest to highest levels of deprivation (Department for Communities and Local Government. English indices
of deprivation 2010, 2010). A normally distributed population would have equal quintile groups, that is, 20% of participants within each group.
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3.4.2 | Secondary outcomes
There was no statistically significant difference between
SMILE (UK) and TAU according to the secondary out-
come measures, including anxiety and depression scores.
All effect sizes were around  0.2 SD or less, indicating
small differences.27 All results are presented in Table 4. A
paper reporting health economic outcomes will be pub-
lished subsequently.
4 | DISCUSSION
4.1 | Summary of findings
We adapted a 2-day, group self-management course devel-
oped for German speakers, trained facilitators to deliver it
in the context of the NHS and piloted the course with vol-
unteers.12 Neurologists invited PWE who attended clinics
during the prior year to a trial of the course, and 37% of
those eligible consented. Twelve months after recruitment,
82% completed outcome assessments. Despite indications
that treatment fidelity was high,15 QoL was not changed
significantly by the intervention, nor were other outcomes,
including psychological symptoms.
4.2 | Strengths
This is the largest RCT conducted thus far on a discrete
self-management education course for people with epi-
lepsy.28 We successfully recruited our required sample size
and had high follow-up rates14 indicating that our results
were not underpowered.
We recruited a large group of adults with poorly controlled
epilepsy from routine specialist clinics, in a metropolitan area,
featuring multiethnicity, high resident turnover, and social
deprivation. Our recruitment and retention rates were rela-
tively high, compared to trials with volunteer groups, with
limited ethnic variation and little social deprivation.28 There-
fore bias was reduced, and our evidence can be generalized to
similar populations in resource-rich countries.
The course required people with chronic, drug-resistant
seizures to spend time and effort in completing assessments
and travel to attend the course. Relatively high response and
retention rates suggest that the intervention was not only
acceptable but also attractive to PWE. Findings from an
accompanying process evaluation with in-depth interviews
with participants who completed SMILE (UK) support this
interpretation.29 In the UK, self-management courses have
been evaluated for type 1 diabetes, and are offered freely to
service users with diabetes in the same region.10,11 Recruit-
ment to the diabetes trial and to the evidence-based courses
was 17% and 27%, respectively.10,11 In comparison, recruit-
ment to the SMILE (UK) trial was 37%, and of those random-
ized to the intervention 72% attended at least 2 of 4 sessions.
Thus 27% of PWE attended the course, even though this was
an untested research context.
4.3 | Limitations
The main outcome variable stipulated by our funder was
QoL, and we chose an epilepsy-specific measure. A recent
review found that QoL improved in some self-management
interventions, specifically when psychological co-morbidity
was addressed.30 A global review of resource-rich and
resource-poor countries was published and reported that the
mean QOLIE-31 score was 60 for all PWE.31 In UK pri-
mary care, a longitudinal study in 2014 found a mean score
of 70.32 However, 60% of PWE in primary care do not
have recurring seizures.2 In contrast, all the PWE recruited
to our trial had frequent seizures, managed by specialists,
and their baseline mean QOLIE-31 score was 62. Given
the severity of their condition, this score may be near a
ceiling for such patients, and therefore difficult to change.
In addition, our group of PWE have lived with epilepsy for
a median of 18 years, and a 2-day course may have come
too late in their illness trajectory to effect significant and
long-lasting change.
Travel to the course and anxiety about meeting others
were barriers that prevented some from enrolling in the
trial or attending the intervention. This could be mitigated
by offering other types of telephone- or Internet-based
interventions; however, they have their own disadvantages.
Some participants reported difficulties in reading the work-
book and following aspects of the course. A web-based
program would likely to be challenging for them. Regard-
less of the method used to deliver an intervention, a group
course does reduce the isolation and sense of stigma that
PWE feel.29
In general, recall of information and events decrease
over time. Recurring seizures and depression additionally
may reduce recall among PWE.33 We did not assess mem-
ory impairment in our group, not wanting to add to the
assessment length, exclude patients based on this, or deter
patients by additional testing. However, in our process
evaluation, we found that some participants described
TABLE 3 Reasons for withdrawal
Reasons
Intervention
n = 42
TAU
n = 31
Adverse event, unrelated to intervention 1 0
Not interested in course 0 1
No longer wanted to complete assessments 7 9
No longer has diagnosis of epilepsy 1 0
Unable to contact participant 32 21
Unknown 1 0
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difficulties remembering the course and doing things in
everyday life.29 In the context of the group’s characteristics
and the complex process of changing,6 it is possible that
aspects of QoL and other outcomes could improve immedi-
ately after a course, but not be maintained 6 or 12 months
later.
4.4 | Interpretation
The result of our RCT is compatible with the null hypothe-
sis that a 2-day course is no more effective in changing
QoL than usual medical care for PWE with persistent sei-
zures who see specialists. Not all interventions that show
promise in early efficacy trials are supported by subsequent
pragmatic late phase trials. In the UK, the National Institute
of Health Research (NIHR) Health Technology Assessment
program is the major funder of pragmatic trials, and over
two thirds of such trials have negative findings.34 This is
more common for complex interventions than for drug tri-
als.34 Reasons that positive findings in exploratory studies
cannot be replicated in late phase trials include the follow-
ing: differences in design, including not randomizing
patients in small studies, outcome measures, and primary
endpoints; initial false-positive results, for example, due to
bias and imbalance in study arms; and false-negative
results in late phase trials, when the target study population
is different, for example, people with poorly controlled epi-
lepsy may require different or more intense intervention to
benefit.34
Complete seizure freedom is a known contributor to
QoL. Not observing a decrease in seizures following the
intervention may explain the lack of change in QoL. How-
ever, using our baseline data, we found that seizure fre-
quency was only weakly associated with QoL. We found
psychological distress was most associated with lower QoL
in our group of PWE.26 There is no literature evidence to
suggest that a solely educational intervention has ever chan-
ged QoL after 12 months in people with epilepsy.28 In pre-
vious trials participants have been followed for no longer
than 6 months, and results were negative for total mean
QoL changes, including in the MOSES trial.9,28 One trial in
a resource-poor country with 144 participants at the 6-
month follow-up reported that QoL did change signifi-
cantly.35 However, baseline mean QoL score in the inter-
vention group was about 10 points lower than is usual in
resource-rich countries. So, low scores at baseline may have
provided more scope for improvement. In addition, that
intervention consisted of 5 components, including a course,
plus regular one-to-one advice and monitoring.35 A review
of interventions for long-term conditions generally has
emphasized the importance of integrating and reinforcing
self-management education, with other, preferably routine,
advice and monitoring.8 This integration and reinforcementT
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has been described in 2 epilepsy trials; the second one
included a course plus nurse-led monitoring.35,36
In the MOSES trial, participants were recruited by
advertising; there was no minimum seizure requirement to
participate, 42% had no seizure in the prior 6 months, and
there was less comorbidity (MOSES: 35% vs SMILE
[UK]: 50%). Analyses were carried out based on a per pro-
tocol approach to target efficacy. However, this approach
no longer retains the benefits of randomization and raises
the possibility of selection bias. Consistent with this, the
median duration of epilepsy was significantly lower in the
MOSES intervention arm once noncompleters were
dropped from the trial sample (MOSES control: 18.2 years,
MOSES intervention: 13.5 years, P = .034).9 Six months
after a course, people with less frequent seizures, shorter
epilepsy duration, and less comorbidity were, and may gen-
erally be, more likely to remember epilepsy-related infor-
mation, increase their sense of control, and by better self-
management, reduce the frequency of their seizures.9
At baseline, seizure frequency of SMILE (UK) partici-
pants was higher than in MOSES, with 70% experiencing
≥10 seizures per year. Psychological symptoms were
reported frequently, with 54% reporting current anxiety
symptoms and 28% reporting current depression symptoms
at borderline or case-level. There was much variation in
QoL scores from 24.5 to 97.6, and it was most strongly
associated with presence or absence of psychological symp-
toms.26 This has also been reported elsewhere.31,37
Nevertheless, despite their psychosocial distress and dif-
ficulties with travel for those with frequent seizures, 74%
of those randomized attended all or some of the course.
Our analysis of baseline measures also found that 63% of
participants felt stigmatized, a concept which describes
feelings of shame. When a subgroup of participants were
interviewed after the intervention, they said that they val-
ued sharing their experiences with people like them; feeling
“less alone” improved their self-acceptance and confidence
to talk about and manage their epilepsy subsequently.29 In
other stigmatized conditions, there has been more research
on interventions designed specifically to address
stigma.38,39 Our findings support the idea that working in
groups promotes individual self-confidence to manage their
condition, which may be a precursor to self-mastery.6,38,39
Participants suggested that such groups should be provided
early on in epilepsy.
4.5 | Implications for research
In the evaluation of stand-alone education courses for
PWE, on the basis of this RCT and a literature review,28
QoL is not an appropriate outcome to measure the benefits
of an educational course. An important feature of PWE and
persistent seizures is the high prevalence of psychological
distress, which is also a major correlate of QoL. A few
small trials suggest that cognitive behavioral therapy or
acceptance and commitment therapy might improve out-
comes, including QoL.28 High quality trials of psychologi-
cal treatments for PWE are a priority in the future.
An important feature in epilepsy is the stigma that a
high proportion of PWE feel. Future evaluations may well
benefit from looking at the evidence on complex interven-
tions for other stigmatized, long-term conditions.38,39 This
might lead to testing group interventions for PWE, to eval-
uate whether self-esteem and self-mastery can be improved
by sharing feelings and experiences in groups preferably
early on after diagnosis.
As a way to increase participation and to offer continued
education, use of digital tools and booster sessions, in person
or via telephone, could mitigate the effects of transportation
issues and memory difficulties.35,36 However, if self-man-
agement interventions are to combat social isolation and
stigma, some element of face-to-face sharing is beneficial.
4.6 | Implications for health care
Our findings suggest that clinicians in the UK, in common
with those in other countries, either do not diagnose or do
not have the capacity to effectively treat the psychological
impairment that frequently accompanies epilepsy, and this
is associated with lower QoL. Luoni has suggested a “diag-
nostic gap” in depression for PWE.37 There may be an
even larger gap in the diagnosis/management of anxiety
symptoms.40 A brief symptom questionnaire could help to
identify psychological comorbidity in routine care. This is
important as depression is associated with poor drug-adher-
ence, poor epilepsy control, and risk of premature death.3–5
When clinicians invite PWE who have attended routine
clinics to participate in group courses, a relatively large
proportion attend and report that courses help redress their
sense of being alone and low self-confidence. In the
absence of courses, clinicians could encourage PWE to join
user self-help groups, and explicitly endorse the value of
such groups in consultations with patients.
PWE may need to cope with cognitive issues, including
memory impairment, psychological distress, and social
stigma. Because of this, their health care will most opti-
mally include a biopsychosocial approach such as the fol-
lowing: (1) courses with digital offerings, divided into
sessions which could be repeated, and which may target
cognitive ability levels, assessed in advance; (2) psycholog-
ical interventions; and (3) peer-group work provided in per-
son, by phone, or through social media.23,41 Despite being
difficult to test, multifaceted interventions are most likely
to help people improve self-management of chronic condi-
tions.6,8 More research is needed, as poor epilepsy control
is associated with more health service use and a higher
RIDSDALE ET AL. | 1059
incidence of premature death.1,2 In England, the epilepsy
death rate is rising, and compared to people with epilepsy
living in the least-deprived areas, those living in the most-
deprived areas experience a death rate 3 times as high.1,42
It is therefore vital to improve on health care for people
with epilepsy.28
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